Interesting. That would explain why it's not a primary outcome in our trial, and I suppose based on your explanation that it was included as a secondary outcome just to check that motor skills do not degrade from baseline. You have drug trial experience, so what do you think? I can think of no other reason why it would be included as an "outcome" at all, given that the company surely (?) would anticipate the negative cholinergic implications of 2-73 in PD motor activity.
It's always good to point out that we're talking about experimental compounds for complex diseases. Not magic beans.
Market Data 
Markets 
AI
